IAVI
Advancing evidence-informed in-country decision-making for new TB vaccine introduction: A responsive and integrated vaccine modelling approach from India
As new TB vaccines move into late-stage development, it is imperative for high-burden
countries like India to ensure timely and effective evidence-generation to inform decision-making
and accelerate vaccine development and introduction. To enable this, an in-country vaccine
mathematical modelling effort has been initiated in India.
IGRA prevalence study
A cross-sectional study to determine IGRA positivity rate to assess eligibility for participation in tuberculosis (TB) vaccine efficacy trials
Navigating the unknown: Ensuring equitable TB vaccine access to maximize health impact
A scoping literature review is underway to identify key principles and strategies from
existing vaccine allocation frameworks. The review focuses on vaccines utilized in routine and
emergency contexts, including malaria, COVID-19, dengue, and meningococcal vaccines, among
others.
Evolution of Tuberculosis Vaccine Modelling studies: Insights from studies in India
Focusing on India, we performed a scoping review to identify and evaluate studies that have used mathematical modeling to assess the epidemiological and economic
impact of TB vaccine introduction in India
New tuberculosis vaccines are in late-stage trials, but how confident is the public in high burden countries in vaccines?
With tuberculosis (TB) vaccine candidates in late-stage trials, it is important to prepare for implementation to avoid delays upon licensure. General confidence in vaccines has been identified as an anticipated barrier to introducing new TB vaccines. In the absence of detailed TB specific vaccine acceptability and confidence data, we analysed currently available vaccine confidence data in countries appearing on one of the World Health Organization (WHO) high burden lists to investigate vaccine confidence in countries with a high TB burden
Forecasting TB vaccine demand to support supply and procurement planning
We present insights from two workshops with global health funders, academics, and in country TB and vaccine decision-makers and estimates of potential global demand for TB vaccines
using a bottom-up, constrained demand forecasting model. The model was informed by the
workshops, publicly available target product profile, landscape assessment of vaccines in
development, information from proxy vaccines sourced from the WHO databases and peer reviewed literature, and interviews with TB and vaccine experts
Financing and policy innovation to advance TB vaccines through licensure: A G20 policy proposal
The authors developed two T20 policy briefs proposing recommendations to enhance
G20 leadership and bring TB vaccines through licensure: Investment Toolbox to Advance TB Vaccine
R&D through Joint Action (2023); and Elevating Leadership of HBC G20 States in TB Vaccine R&D and
Delivery (2024). The briefs were informed by extensive literature research and aligned with global
initiatives for TB and TB vaccine R&D.
The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug resistant tuberculosis in India and China
We investigated the epidemiologic impact, cost-effectiveness, and budget impact of hypothetical novel prophylactic prevention of disease TB vaccines on RR/MDR-TB in China and India.
Global TB vaccine partnership
The Global Tuberculosis Vaccine Partnership (GTBVP) is a forum for key stakeholders in TB vaccine R&D to identify and address barriers impeding TB vaccine R&D and to discuss R&D priorities in order to help inform funding decisions